Novo Nordisk Crashed 15% After Its Next-Generation Weight-Loss Drug Failed to Match Eli Lilly's, and the $150 Billion GLP-1 Race Just Got Its First Clear Winner
Novo Nordisk shares plunged 15% after its CagriSema weight-loss drug failed to demonstrate non-inferiority versus Eli Lilly's tirzepatide, reshaping the $150 billion GLP-1 market overnight.